Skip to main content
. 2017 Feb 18;8(14):23061–23072. doi: 10.18632/oncotarget.15481

Figure 2. Clonal evolution during TKI therapy as assessed by HUMARA.

Figure 2

The HUMARA assay was performed with peripheral blood mononuclear cells in certain time intervals (from 2005 = month 0) as indicated. As assessed by HUMARA, a monoclonal pattern was seen in 2005 (month 0) and at the time of relapse with a Ph-negative clone when bone marrow (BM) fibrosis was detected (months 95–97). However, after successful treatment with dasatinib and nilotinib (months 9–22), a polyclonal pattern was obtained by HUMARA testing.